Future Science OA最新文献_第4页

A new approach to the intelligent decision support system for individual hearing aid selection and acquisition. 个人助听器选择与获取智能决策支持系统的新方法。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-08-11 DOI: 10.1080/20565623.2025.2543175

Rolandas Drejeris, Saulius Vaitkus, Greta Minelgaite, Aurelija Kustiene, Egle Drejeriene

{"title":"A new approach to the intelligent decision support system for individual hearing aid selection and acquisition.","authors":"Rolandas Drejeris, Saulius Vaitkus, Greta Minelgaite, Aurelija Kustiene, Egle Drejeriene","doi":"10.1080/20565623.2025.2543175","DOIUrl":"10.1080/20565623.2025.2543175","url":null,"abstract":"Background: The intelligent decision support system (IDSS) is designed for patients to acquire hearing aids that better meet their needs, because they often agree to pay from their funds for a better, more customized hearing aid.Objective: The article aims to present the IDSS for selecting personal hearing aids in healthcare institutions.Methods: The article proves that the SAW (simple additive waiting) multi-criteria evaluation method is the most suitable for creating the IDSS. Hearing aids are evaluated according to 12 reasonable criteria, which are differentiated into two groups. The proposed methodology is flexible, allowing for changing the significance of differentiated criteria groups.Results: The created IDSS system helps increase the effectiveness of choosing the best hearing aid. Even 92% of the surveyed patients positively evaluated the choice of hearing aid. This situation indicates greater patient satisfaction than usual when selecting these measures.Conclusion: The proposed IDSS is suitable for adaptation in a computer program, and such a solution greatly facilitates the selection of a hearing aid. Applying the proposed IDSS makes the choice more objective, thus better meeting patients' needs.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2543175"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thymic rebound after adjuvant chemotherapy in breast cancer: a case report. 乳腺癌辅助化疗后胸腺反弹1例。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-09-11 DOI: 10.1080/20565623.2025.2560241

Myriam Ayari, Sarah Ben Azouz, Amira Chehaider, Sarra Ben Rejeb, Taieb Jomni

{"title":"Thymic rebound after adjuvant chemotherapy in breast cancer: a case report.","authors":"Myriam Ayari, Sarah Ben Azouz, Amira Chehaider, Sarra Ben Rejeb, Taieb Jomni","doi":"10.1080/20565623.2025.2560241","DOIUrl":"10.1080/20565623.2025.2560241","url":null,"abstract":"Chemotherapy, especially for malignant tumors, can affect the thymus, leading to its atrophy and a decreased production of naïve T lymphocytes. However, regenerative process can occur in children and rarely in adults manifesting as thymic hyperplasia. A 49-year-old female patient was diagnosed with stage I breast cancer. She was treated with surgery, adjuvant chemotherapy followed by radiotherapy and hormonotherapy. Follow-up computed tomography scan showed a mediastinal retro-sternal mass, raising concern for tumor recurrence. However, no other signs of relapse were evident. A thymic rebound was suspected, with the lesion presenting as a triangular-shaped mediastinal mass suggestive of thymic morphology and consisting of mixed fat and soft tissue density with smooth borders. Close monitoring was then decided. A follow-up CT scan of the chest showed regression of the mediastinal mass. The diagnosis of thymic rebound after chemotherapy was then retained. The patient is currently in remission, seven years from her original diagnosis of breast cancer. Thymic hyperplasia after chemotherapy can rarely occur in adults. Clinicians should be aware of this unusual presentation to prevent needless investigation and therapy.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2560241"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reporting and representation of race and ethnicity data in phase III clinical trials for hematological malignancies. 血液学恶性肿瘤III期临床试验中种族和民族数据的报告和代表。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-09-22 DOI: 10.1080/20565623.2025.2563483

Tianyi Wang, Ambily Banerjee, Dina Gifkins

{"title":"Reporting and representation of race and ethnicity data in phase III clinical trials for hematological malignancies.","authors":"Tianyi Wang, Ambily Banerjee, Dina Gifkins","doi":"10.1080/20565623.2025.2563483","DOIUrl":"10.1080/20565623.2025.2563483","url":null,"abstract":"Background: The recruitment of underrepresented racial and ethnic groups in clinical trials remains a challenge.Methods: The ClinicalTrials.gov database was queried for phase III trials related to non-Hodgkin lymphoma (NHL), leukemia, and multiple myeloma (MM). A reference population was sourced from the Surveillance, Epidemiology, and End Results (SEER) database.Results: A total of 53,821 pooled participants from 119 phase III trials were included in the analyses. Race and ethnicity data were reported in 95.8% and 81.5% of trials, respectively. Globally, the majority of participants were predominantly White (77.3%), followed by Asian (8.2%), Black/African American (5.4%), American Indian/Alaska Native (0.4%), and Native Hawaiian/Other Pacific Islander (0.2%), while Hispanic/Latino individuals constituted 11.0% of trial participants. In comparison to data in SEER, the proportions were lower for Asian/Pacific Islander and Hispanic/Latino across all cancers, and for Black/African American and American Indian/Alaska Native in leukemia and MM in US only trials.Conclusions: Despite progress, reporting and representation of non-White population remain insufficient in trials. Innovative strategies to enhance representation in trial enrollment are warranted, as well as the utilization of real-world data to establish recruitment goals by more effectively assessing the demographic and geographic distribution of target patient populations.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2563483"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioanalytical method validation to quantify ketorolac in human vitreous and aqueous via surrogate matrix of human plasma. 通过人血浆替代基质定量人玻璃体和水溶液中酮罗拉酸的生物分析方法验证。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-19 DOI: 10.1080/20565623.2025.2476866

Prajita Pandey, Brianna A White, Colin Goswell, Neelanjan Bose, Sara Butterworth Connell, Nicolee Schulze, Jim Nevelos, Ana Najafi, Ramin Najafi, Ryan K Cheu

{"title":"Bioanalytical method validation to quantify ketorolac in human vitreous and aqueous via surrogate matrix of human plasma.","authors":"Prajita Pandey, Brianna A White, Colin Goswell, Neelanjan Bose, Sara Butterworth Connell, Nicolee Schulze, Jim Nevelos, Ana Najafi, Ramin Najafi, Ryan K Cheu","doi":"10.1080/20565623.2025.2476866","DOIUrl":"10.1080/20565623.2025.2476866","url":null,"abstract":"Purpose: Intracameral phenylephrine 1.0%/ketorolac 0.3% (OMIDRIA®) is used during cataract surgery to prevent intraoperative miosis and reduce postoperative pain. Although studied in beagles, no human data exist showing the duration ketorolac remains in the eye postoperatively. A clinical trial measuring ketorolac concentrations in aqueous/vitreous samples necessitated the development of a validation process for acquiring these measurements. Due to limited human aqueous/vitreous humor sample availability, a bioanalytical method was developed and validated to quantify ketorolac levels using human plasma as a surrogate matrix.Methods: The developed process involves extracting ketorolac and its internal standard (ketorolac-d5) from plasma as a surrogate for aqueous and vitreous humor using a protein precipitation sample preparation technique, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis.Results: The validated method can be successfully applied for quantitation of ketorolac over a concentration range of 2.5 ng/mL to 5000 ng/mL. The method met the acceptance criteria with respect to selectivity, specificity, precision, accuracy, linearity, dilution integrity, and stability.Conclusions: The validated method can use plasma as a surrogate matrix for quantitation of ketorolac in aqueous and vitreous humor, thereby eliminating the need to procure human vitreous and aqueous samples for validation prior to initiation of a clinical trial.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2476866"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dysadherin expression in prostatic adenocarcinoma and its relationship with E-cadherin and β-catenin. 前列腺腺癌中粘附异常蛋白的表达及其与E-cadherin和β-catenin的关系。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-04-28 DOI: 10.1080/20565623.2025.2494972

Rinë Limani, Labinota Kondirolli, Brikenë Blakaj Gashi, Monika Ulamec, Božo Krušlin

{"title":"Dysadherin expression in prostatic adenocarcinoma and its relationship with E-cadherin and β-catenin.","authors":"Rinë Limani, Labinota Kondirolli, Brikenë Blakaj Gashi, Monika Ulamec, Božo Krušlin","doi":"10.1080/20565623.2025.2494972","DOIUrl":"https://doi.org/10.1080/20565623.2025.2494972","url":null,"abstract":"Background: We analyzed immunoexpression of Dysadherin, E-cadherin and ß-catenin proteins in prostate.Methods: 53 radical prostatectomy specimens were included. Dysadherin, E-cadherin and ß-catenin were evaluated in prostatic adenocarcinoma and in adjacent non-tumorous tissue, and correlated with clinicomorphological features in prostatic adenocarcinoma.Results: We report cytoplasmic/membraneous and nuclear staining for Dysadherin in prostatic tissue. Cytoplasmic/membraneous expression was stronger in prostatic adenocarcinoma when compared to adjacent non-tumorous prostatic tissue (p < 0.001).Dysadherin positively correlated with T status (rho = 0.326, P = 0.017) and Grade Group (rho = 0.278, P = 0.044). We report no correlation with recurrence, surgical margins status, sPSA and N status. E-cadherin was negatively correlated with recurrence (rho = -0.297, P = 0.031), T status (rho = -0.430, P = 0.001), Grade Group (rho = -0.558, P < 0.001) and positive surgical margins (rho = -0.404, P = 0.003). ß-catenin negatively correlated with Grade Group (rho = -0.557, P < 0,001). No correlation was observed between Dysadherin and E-cadherin and Dysadherin and ß-catenin expression.Conclusion: Our results suggest a potential role for Dysadherin in tumor progression. No significant correlation between Dysadherin and E-cadherin or ß-catenin indicates potential independence of Dysadherin in its regulatory role in prostatic adenocarcinoma.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2494972"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using IgY for diagnosis of respiratory infections: practical application in COVID-19. 利用IgY诊断呼吸道感染：在COVID-19中的实际应用

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-08-18 DOI: 10.1080/20565623.2025.2546245

Cícero Matheus Lima Amaral, Valdester Cavalcante Pinto Júnior, Daniel Freire Lima, Hellen Paula Silva da Costa, Danúbio Andrade Bezerra Farias, João Xavier da Silva Neto, Luiz Francisco Wemmenson Gonçalves Moura, Bruno Bezerra da Silva, Ednardo Rodrigues Freitas, Maurício Fraga Van Tilburg, Maria Izabel Florindo Guedes

{"title":"Using IgY for diagnosis of respiratory infections: practical application in COVID-19.","authors":"Cícero Matheus Lima Amaral, Valdester Cavalcante Pinto Júnior, Daniel Freire Lima, Hellen Paula Silva da Costa, Danúbio Andrade Bezerra Farias, João Xavier da Silva Neto, Luiz Francisco Wemmenson Gonçalves Moura, Bruno Bezerra da Silva, Ednardo Rodrigues Freitas, Maurício Fraga Van Tilburg, Maria Izabel Florindo Guedes","doi":"10.1080/20565623.2025.2546245","DOIUrl":"10.1080/20565623.2025.2546245","url":null,"abstract":"Aim: The COVID-19 pandemic underscores the need for expanded diagnostic tools to combat respiratory pathogens with pandemic potential, particularly in developing countries. This study aimed to create a Dot Blotting test utilizing IgY antibodies for acute respiratory infection diagnosis, with COVID-19 as the disease model.Methods: Leghorn chickens were immunized with precipitated SARS-CoV-2 virus, and IgY antibodies were purified via ammonium sulfate precipitation and titrated by ELISA. Dot Blotting detected viral antigens in saliva samples, demonstrating efficacy comparable to ELISA tests.Results: The IgY antibody was successfully produced and purified, obtaining a titration of 1:16,000. The ability of IgY to detect SARS-CoV-2 in clinical saliva samples showed promising results in terms of accuracy (91.3%), sensitivity (92.5%), specificity (90.0%), positive predictive value (PPV) (90.2%), negative predictive value (NPV) (92.3%), and Cohen's Kappa (0.825).Conclusion: Chicken antibodies proved effective for early and accurate diagnosis of respiratory infections, including COVID-19. This study validates the efficacy of chicken antibodies in diagnosing respiratory infections, supporting pandemic response in developing nations. Expanding diagnostic capabilities is crucial for combating respiratory pathogens.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2546245"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144872656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endovascular thrombectomy of acute ischemic stroke patients with systemic lupus erythematosus: two case reports. 急性缺血性脑卒中合并系统性红斑狼疮患者血管内血栓切除术2例报告。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-07-18 DOI: 10.1080/20565623.2025.2534329

Weilong Hua, Lijun Wang, Hongye Xu, Hongyu Ma, Yongxin Zhang, Hongjian Shen, Xiaoxi Zhang, Pengfei Xing, Pengfei Yang

引用次数: 0

Liposomal honokiol enhance the anti-tumor effect of bevacizumab in glioblastoma by inhibiting autophagy. 脂质体厚朴醇通过抑制自噬增强贝伐单抗在胶质母细胞瘤中的抗肿瘤作用。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-08-13 DOI: 10.1080/20565623.2025.2546232

Pei Xun, Jiabao Zong, Shenglan Li, Wenbin Li

{"title":"Liposomal honokiol enhance the anti-tumor effect of bevacizumab in glioblastoma by inhibiting autophagy.","authors":"Pei Xun, Jiabao Zong, Shenglan Li, Wenbin Li","doi":"10.1080/20565623.2025.2546232","DOIUrl":"10.1080/20565623.2025.2546232","url":null,"abstract":"Aims: To investigate whether liposomal honokiol enhances the anti-tumor effect of bevacizumab (BEV) in glioblastoma (GBM) and explore its underlying mechanism.Materials & methods: A U87 cell xenograft model in nude mice was used, with groups: model (M), M + liposomal honokiol (Lip-HNK), M + BEV, and M + Lip-HNK + BEV. Tumor volume, body weight, serum levels of VEGF, VEGFR, TNF-α, and Caspase-3, and expressions of autophagy-related (Beclin-1, LC3) and UPR-related (IRE1, GRP78) molecules in tumor tissues were detected.Results: Compared with monotherapy, the combination of Lip-HNK and BEV significantly reduced tumor volume and tumor index, decreased serum levels of VEGF, VEGFR, and TNF-α, while increasing serum caspase-3. Further mechanistic studies showed that the combination of Lip-HNK and BEV significantly reduced the expression of Beclin-1, LC3, IRE1, and GRP78 in tumors.Conclusions: Lip-HNK may promote the anti-GBM effect of BEV by inhibiting autophagy mediated by the UPR response.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2546232"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reduced recurrence of prostate cancer with novel autologous cancer vaccine (FK- PC101) post-prostatectomy: long-term results from a single-center phase 1/2 study. 前列腺切除术后使用新型自体癌疫苗（FK- PC101）减少前列腺癌复发：一项单中心1/2期研究的长期结果

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-08-29 DOI: 10.1080/20565623.2025.2550917

D M O Freitas, A C Stein, M Berger, F T Kreutz

{"title":"Reduced recurrence of prostate cancer with novel autologous cancer vaccine (FK- PC101) post-prostatectomy: long-term results from a single-center phase 1/2 study.","authors":"D M O Freitas, A C Stein, M Berger, F T Kreutz","doi":"10.1080/20565623.2025.2550917","DOIUrl":"10.1080/20565623.2025.2550917","url":null,"abstract":"Background: Prostate cancer is a major contributor to cancer-related mortality in men. High-risk patients, particularly those with biochemical recurrence (BCR) following radical prostatectomy (RP), face poor long-term outcomes. Adjuvant options such as radiotherapy, chemotherapy, and androgen deprivation therapy (ADT) have shown limited benefit in this setting.Methods: This retrospective analysis evaluated the safety, feasibility, and efficacy of FK-PC101, an autologous immunomodulated tumor cell vaccine, in high-risk post-RP patients. Data were drawn from the FK002-2001 trial, a phase 1/2, non-randomized, open-label study conducted in Brazil. A total of 62 patients were included: 23 in the vaccine group and 39 controls. Primary endpoints were safety and feasibility; secondary endpoints included biochemical recurrence-free survival (BRFS) and overall survival (OS).Results: The vaccine was well tolerated, with most adverse events being grade 1-2 local reactions. PSA recurrence at 4 years was significantly lower in the vaccine group (11.8%) when compared to controls (36.8%; P = 0.0453). OS did not differ significantly between groups. A higher rate of erectile dysfunction was observed in the vaccine group (P = 0.047).Conclusion: FK-PC101 demonstrated safety and potential clinical benefit in reducing prostate specific antigen (PSA) recurrence after RP in high-risk prostate cancer patients. These findings support further evaluation in a randomized phase 2 trial.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2550917"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144950394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Finger replantation in Jordan: evaluating the knowledge, attitudes, practices, and barriers among doctors and medical students. 约旦手指再植：评价医生和医学生的知识、态度、做法和障碍。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-09-08 DOI: 10.1080/20565623.2025.2557782

Saleh Abualhaj, Mosleh M Abualhaj, Lina Alshadfan, Anas As'ad, Mohamad Kharashgah, Tayseer A Al-Tawarah, Abed Alazeez Alkhatib, Mohammad Aljaidi

{"title":"Finger replantation in Jordan: evaluating the knowledge, attitudes, practices, and barriers among doctors and medical students.","authors":"Saleh Abualhaj, Mosleh M Abualhaj, Lina Alshadfan, Anas As'ad, Mohamad Kharashgah, Tayseer A Al-Tawarah, Abed Alazeez Alkhatib, Mohammad Aljaidi","doi":"10.1080/20565623.2025.2557782","DOIUrl":"10.1080/20565623.2025.2557782","url":null,"abstract":"Background: Finger replantation is a complex microsurgical procedure that requires optimal conditions for success. Understanding the knowledge and awareness of healthcare professionals regarding finger preservation and replantation can help improve outcomes for patients with amputated fingers.Methods: A cross-sectional survey was conducted among healthcare professionals, including clinical years medical students, surgical residents, and specialists. The survey assessed participants' knowledge of factors influencing the finger replantation success, the appropriate management of amputated fingers before surgery, the ideal time for replantation, and key considerations for finger preservation.Results: Among 197 participants, 81.2% correctly identified finger replantation as a surgical procedure to reattach a severed finger. However, 9.6% incorrectly believed it was a technique to preserve the finger for later reattachment. The most frequently reported barriers to performing finger replantation included lack of training or expertise (78.2%), limited access to specialized surgical instruments (66.5%), and financial constraints (61.9%). Significant differences were found across professional groups regarding perceived barriers, particularly in terms of training, access to surgical instruments, and infrastructure.Conclusion: While general knowledge of finger replantation is high, key misconceptions and barriers; like limited training, resources, and funding, persist. Improving education, infrastructure, and specialized programs is vital to expanding access and enhance outcomes.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2557782"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12427489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0